Total revenues - Summary of our main contracts (Details) - EUR (€) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Period over which to recognize the drug discovery platform revenue | 10 years | ||
| Maximum Extension Period For Specific Program | 3 years | ||
| Gilead | |||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Royalties | € 10,604,000 | € 9,466,000 | € 10,726,000 |